Creative Commons source reading · ALS and frontotemporal degeneration
Neurofilament light chain: a biomarker for genetic frontotemporal dementia.
Lieke H Meeter; Elise G Dopper; Lize C Jiskoot; Raquel Sanchez-Valle; Caroline Graff; Luisa Benussi; Roberta Ghidoni; Yolande A Pijnenburg; Barbara Borroni; Daniela Galimberti; Robert Jr Laforce; Mario Masellis; Rik Vandenberghe; Isabelle Le Ber; Markus Otto; Rick van Minkelen; Janne M Papma; Serge A Rombouts; Mircea Balasa; Linn Öijerstedt; Vesna Jelic; Katrina M Dick; David M Cash; Sophie R Harding; M Jorge Cardoso; Sebastien Ourselin; Martin N Rossor; Alessandro Padovani; Elio Scarpini; Chiara Fenoglio; Maria C Tartaglia; Foudil Lamari; Christian Barro; Jens Kuhle; Jonathan D Rohrer; Charlotte E Teunissen; John C van Swieten
Originally published in Annals of clinical and translational neurology · 2016-07-01
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Objective To evaluate cerebrospinal fluid (CSF) and serum neurofilament light chain (NfL) levels in genetic frontotemporal dementia (FTD) as a potential biomarker in the presymptomatic stage and during the conversion into the symptomatic stage. Additionally, to correlate NfL levels to clinical and neuroimaging parameters. Methods In this multicenter case-control study, we investigated CSF NfL in 174 subjects (48 controls, 40 presymptomatic carriers and 86 patients with microtubule-associated protein tau (MAPT), progranulin (GRN), and chromosome 9 open reading frame 72 (C9orf72) mutations), and serum NfL in 118 subjects (39 controls, 44 presymptomatic carriers, 35 patients). In 55 subjects both CSF and serum was determined. In two subjects CSF was available before and after symptom onset (converters). Additionally, NfL levels were correlated with clinical parameters, survival, and regional brain atrophy.
Discussion
The present study on a large cohort of carriers of pathogenic GRN, MAPT or C9orf72 mutations showed eight‐fold higher CSF NfL levels in patients than in presymptomatic carriers and controls. CSF NfL discriminated presymptomatic carriers from patients and might be useful to determine conversion. Serum NfL correlated highly with CSF NfL and showed a similar elevation in patients. Additionally, NfL levels in patients correlated with disease severity, brain atrophy, annualized brain atrophy rate, and survival.
Editorial reading guide
- Was the evidence cross-sectional, longitudinal or experimental?
- How did the authors account for age, disease stage and differences among participants?
